Fig. 3From: Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trialBCVA change progression during the 24-week study period in both groups. After one week of follow-up, there is significant improvement in BCVA only in the group which underwent pars plana vitrectomy (Group B). In the following visits until week 24, there was no difference in BCVA change between the groupsBack to article page